Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial

Achim Rittmeyer, David R. Gandara, Fairooz F. Kabbinavar et al.|The Lancet|2016

Cited by 4.8k